Abstract: The present invention relates to new oxygen transfer agents which comprise haemoglobin-hydroxyethylstarch conjugates, and processes for their preparation. The invention furthermore relates to the use of the oxygen transfer agents as a blood substitute, plasma expander, perfusion agent, haemodilution agent and/or cardioplegic solution. The invention relates in particular to oxygen transfer agents which comprise a haemoglobin-hydroxyethylstarch conjugate in which the haemoglobin and the hydroxyethylstarch are linked to one another selectively via amide bonds between free amino groups of the haemoglobin and the reducing end group of the hydroxyethylstarch, which is present in oxidized form.

Abstract: Disclosed is the production of starch decomposition products with a narrow molecular weight distribution, based on the treatment of starch or starch derivatives using high-pressure homogenization. The starch decomposition products are obtained in high yields with a narrow molecular weight distribution.

Abstract: An emulsion containing one or several polyunsaturated, long-chain omega-3 and/or omega-6 fatty acids or their pharmaceutically tolerable esters or salts, as well as usual adjuvants and additives, is used to produce an intravenously administered medicament for treating skin diseases, in particular inflammatory skin diseases, as well as diseases of the dermatitis or eczema group. Preferably, fatty acids containing 18-22 carbon atoms, as well as their pharmaceutically tolerable esters of salts, are used. These acids or their pharmaceutically tolerable esters or salts may be used in their pure form or as components of oils, such as fish oil, highly-purified fish oil concentrates, linseed oil, primrose oil, borage oil or soya oil. Specially preferred are the pharmaceutically tolerable esters or salts of said acids, in particular the pharmaceutically tolerable esters, especially those derived from eicosapentaenic acid.

Abstract: The use of a hydroxyethyl starch specification with a molecular weight M.sub.W of 110,000 to 150,000, a substitution level MS of 0.38 to 0.5, a substitution level DS of 0.32 to 0.45, and a C.sub.2 /C.sub.6 ratio from 8 to 20 for improvement of microcirculation in a peripheral arterial circulation disorder, in particular in already existing peripheral arterial occlusive disease in Stage II according to Fontaine. This hydroxyethyl starch specification can be used in suitable concentrations, e.g., as 6 wt.-% or 10 wt.-% solution, whereby these solutions optionally contain conventional adjuvants and additives.

Abstract: The present invention concerns nutriment preparations for humans and animals which are suited in particular for ureamic patients and for clinical nutrition and which contain as an energy substrate at least one glycerid hard to dissolve resp. insoluble in water with at least one branched-chain fatty acid derived from the residue of the general Formula II ##STR1## wherein R designates a methyl residue or an ethyl residue, m designates 0 or 1, preferably 1, and n designates 0 or an even number between 2 and 18, preferably 0 or an even number between 2 and 6 and in particular 0, 2 or 4. The preparations according to the invention are suited for the treatment of severe trauma and sepsis and, in particular, for the treatment of ureamic patients, e.g. during chronic kidney insufficiency, of urea synthesis disorders and for nutrition therapy of acute kidney failure. The preparations may be administered both enterally and parenterally, whereby the customary administration forms, e.g.

Abstract: A container (1) is described for the separate sterile storage of at least two substances and for mixing said substances. Said container comprises a first chamber (2) for storage of a powdery substance (17) and a second chamber (3) for storage of a liquid. While said second chamber (3) preferably consists of polymer layers, chamber (2) is manufactured from a rigid material, prefeably polycarbonate, hard-PVC or polypropylene. Both chambers are connected via the tubular section (10) which is closed by the break-off part (4). For mixing both substances the break-off part (4) is broken off along the weakened line (7). The mixture is taken off through the outlet opening (6). A separate storage of two substances and the sterile mixing of said substances is possible by means of the container (1).

Abstract: A hydroxyethyl starch for use as plasma expander which is obtainable by hydrolytic predegradation of a starch rich in amylopectin, partial hydroxyethylation to a specific substitution degree in the presence of alkali and subsequent hydrolytic degradation to a specific molecular weight, comprises a mean molecular weight of 60,000-600,000 and a substitution degree MS of 0.15-0.5. The ratio of the substitution of C2 to the substitution of C6 of the anhydroglucose units is 8-20 and the substitution degree DS lies in the range from 0.15 to 0.5. A process for the preparation of this hydroxyethyl starch employs 2-chloroethanol as hydroxyethylation agent. The hydroxyethylation is carried out under alkaline conditions at room temperature, the pH value held at a value of about 12 and the temperature held at a value of about 20.degree. C.

Abstract: The present invention describes package units for medical purposes, in particular for receiving and/or storing sterilizable preparations for parenteral uses or dialysis solutions, comprising a container having at least one discharge spout and consisting of polyamide 66 or a laminate of polyamide 66 sheet and polyolefin sheet, the polyolefin sheet being disposed on the side facing the liquid to be stored and the sheet of polyamide 66 being disposed on the outside and the two sheets being bonded together in usual manner by means of an adhesive. The package units may further comprise an inner container or an outer container. The package unit is made in that a container having at least one discharge spout is made from polyamide 66 or the aforementioned laminate, said container filled with the liquid to be stored, then sealed and sterilized and possibly subsequently surrounded after cooling and drying with an outer container of polymeric material.

Abstract: The use of tryptophan containing oligopeptides for the treatment of cerebral disturbances in particular sleeplessness and depression is disclosed. The use of glycyl tryptophan, if desired, in combination with tryptophan itself, is especially preferred.